




AstraZeneca's Impact in Canada

Pioneering science &
economic growth

2026





Contents

3	AstraZeneca in Canada
5	AstraZeneca's Economic Contribution in Canada
7	A Leading Research & Development Footprint in Canada
10	Partnerships & Collaborations
17	Sustainability
19	People & Community
21	Methodology




AstraZeneca in Canada

AstraZeneca is one of the country’s leading pharmaceutical companies, with a growing employee and research and development (R&D) footprint that spans basic research through Phase 3 clinical research. With more than 75 years in Canada, AstraZeneca is supporting better outcomes for patients and helping strengthen the country’s life sciences ecosystem through sustained investment, high-value jobs, and the development of innovative medicines.

This contribution is becoming more deeply rooted in Canada. The acquisition of Fusion Pharmaceuticals, alongside recent investments in AstraZeneca’s growing Mississauga-based footprint, reflects a long-term commitment to Canada as a place to discover, develop, and deliver the next generation of medicines. In Mississauga, this investment includes a new head office, the expansion of its oncology and biopharma R&D Hubs, and the creation of a new Alexion R&D Hub focused on rare diseases.

Beyond the numbers, AstraZeneca is investing in sustainability, future leaders, and community initiatives that help build healthier communities and a more resilient health system.



In 2025, AstraZeneca Canada:



Supported **\$1.3 billion** in economic value across the economy



Directly **employed 2,600 employees**



Supported more than **8,100 jobs** across the country



Spent more than **\$500m in R&D**



Supported the delivery of 184 clinical trials involving **more than 2,000** Canadian patients



It's an exciting moment for AstraZeneca in Canada as we advance the next generation of innovative medicines and expand our research footprint. As a leading science-driven company, we're investing in transformative technologies and modalities that will shape the future of medicine, here in Canada and around the world.

But Canada is at a critical juncture. We lack practical policies that support investment in health and innovation. With the right framework, Canada's life sciences industry can drive investment and economic growth, strengthen health security and sovereignty, create high-quality jobs, and ensure Canadian patients benefit from world-class science.

Gaby Bourbara

President, AstraZeneca Canada






AstraZeneca's Economic Contribution in Canada

AstraZeneca's economic contribution extends well beyond its direct operations. **For every job created at AstraZeneca, two additional jobs are supported elsewhere across Canada** through supply chain partnerships and employee spending in local economies.

In 2025, AstraZeneca supported more than \$1.3 billion of economic activity in Canada and approximately 8,100 jobs nationwide. In addition to the 2,600 individuals employed directly by AstraZeneca and its subsidiaries Alexion Rare Disease, Fusion Pharmaceuticals and Evinova, the company supported more than 5,500 additional jobs indirectly – through its extensive Canadian supply chain partnerships and through employee spending in local economies nationwide.

This employment footprint extends beyond Ontario, which is home to our Mississauga headquarters. Including our supply chain impacts, we support 186 jobs in Alberta, more than 790 jobs in Quebec, 970 jobs in Nova Scotia and roughly 360 jobs in New Brunswick.

The life sciences sector is one of the most innovative and investment-intensive industries in Canada. **AstraZeneca's workforce is at the forefront of productivity and innovation, with the average employee contributing \$240,000 directly to Canadian gross domestic product (GDP) – approximately 57% above the national average for all workers.**



Building on a 75+ Year Legacy in Canada’s Life Sciences

Established in Canada in 1950, AstraZeneca Canada has been a leader in the Canadian life sciences sector for more than 75 years.

Headquartered in Mississauga, Ontario, the company has built one of the largest pharmaceutical talent and research footprints in Canada, with operations spanning the full value chain of pharmaceutical activity: discovery, development, large-scale clinical trials, manufacturing, and commercialization. In Canada, AstraZeneca is comprised of:



Canada has also been designated a global R&D hub for AstraZeneca and Alexion, with teams leading and advancing more than 180 global clinical studies in oncology, biopharma, and rare diseases – some of these studies involving more than 25 countries.

Our Canadian footprint has expanded through milestone investments, including the 2024 acquisition of Hamilton-based Fusion Pharmaceuticals. This \$3 billion acquisition – one of the largest research investments ever made in a Canadian biotechnology company – adds new expertise and capabilities in actinium-based radioconjugates to AstraZeneca, including pioneering research and development, manufacturing, and supply chain operations. Fusion is developing next-generation radioconjugates with the promise to redefine radiotherapy for cancer patients.

In 2024, Evinova established a global hub in Mississauga. Operating as a separate health-tech business within AstraZeneca, Evinova delivers globally-scaled AI and digital health solutions that are evidence-led and science-based to serve clinical trial sponsors, clinical research organizations, clinical trial site care teams, and patients. By bringing to market scaled technology solutions already used globally by AstraZeneca, Evinova optimizes clinical trial design and delivery, reducing the time and cost of developing new medicines, bringing care closer to home for patients, and reducing the burden on health systems.

Together, AstraZeneca’s Canadian operations combine large-scale R&D, clinical trial leadership, and digital innovation, positioning Canada as one of AstraZeneca’s key strategic global R&D and multi-function hubs.



A Leading Research & Development Footprint in Canada

AstraZeneca is one of Canada's leading R&D contributors across all industries. **In 2025 alone, our Canada teams spent \$500.96 million on R&D.**

At the beginning of January 2026, we were delivering approximately 184 active clinical studies across Canada:

These studies involved more than **589 principal investigators**, **376 institutions**, and more than **2,000 Canadian patients nationwide**.



Providing early patient access to next-generation medicines: Clinical trials are the cornerstone of delivering the next wave of life-changing medicines and helping patients live better, longer, more productive lives. Conducting trials in Canada enables local patients to benefit early from medical breakthroughs in disease areas such as breast, gynecologic and lung cancers, haematology, acute kidney failure, and rare diseases like paroxysmal nocturnal hemoglobinuria (PNH).




Building scientific expertise and infrastructure: Providing Canadian researchers and clinicians with important opportunities to build expertise and advance scientific knowledge – contributing to a highly skilled workforce, attracting top talent to Canadian institutions, and strengthening Canada's position as a leader in global health research.




Driving economic growth: Clinical trials attract life sciences investments, create high quality jobs, and accelerate innovation. Their costs – including investigational medicines, diagnostics, and trial-related patient care – are also funded by sponsors, resulting in significant health system savings.



105
Oncology
trials



61
Biopharmaceutical
trials



18
Rare disease
trials



AstraZeneca's continued investment to establish and grow the Alexion R&D hub in Canada underscores our long-term commitment to discovering and developing transformative medicines for people living with rare diseases.

Rare disease research is uniquely challenging. Small, dispersed patient populations, complex biology, and limited understanding of these diseases demand highly specialized science, deep partnerships, and agile trial designs. By expanding our clinical trial footprint across Canada to reach more than 175 rare disease patients across seven provinces, we're not only accelerating access to cutting-edge therapies and generating high-quality evidence locally, we're also strengthening the health ecosystem that makes rare disease innovation possible.

Christina Archer

VP, Development
Operations and R&D Site
Head, Alexion





We're rapidly expanding AstraZeneca's research footprint in Canada, with our Mississauga-based R&D Hubs in Oncology, Biopharma, and Rare Disease playing an increasingly integral role in leading and delivering global clinical studies. Our Canadian clinical team is currently managing over 180 active trials involving more than 2,000 patients nationwide, making AstraZeneca one of the largest clinical research contributors in the country.

Clinical trials are the cornerstone of the next wave of life-changing medicines – conducting them here ensures Canadian patients gain early access to next-generation breakthroughs. They also strengthen the economy by attracting scientific investments, creating high-value life sciences jobs, and providing vital opportunities for local researchers to deepen expertise and advance scientific knowledge.

Krista Olsen

Executive Director, Study Management -
Global Medicines Development, AstraZeneca





Partnerships & Collaborations

In Canada, AstraZeneca's partnerships are helping to strengthen health systems, improve care pathways, support health across diverse communities, and contribute to the health of the planet.

Working with clinicians, patient groups, non-governmental organizations, health systems, and governments, AstraZeneca supports initiatives that advance earlier diagnosis, coordinated treatment and more equitable healthcare delivery while remaining focused on building resilient, sustainable healthcare models.



National

Eureka Fellowship for Youth Changemakers:
Spotlighting Young Sustainability Leaders



National

RAREvolution Scholarship:
Pan-Rare Disease Scholarship Initiative for Youth



Alberta

Lung Health Check in Alberta:
Advancing Patient Care and Health Equity



Quebec

Expert Centre for Complement-Mediated
Rare Diseases at CHU Sainte-Justine



Ontario

Best Care program:
Transforming Patient Care in Lung Health



Best Care program: Transforming Patient Care in Lung Health

AstraZeneca’s long-standing **Best Care** collaboration¹ shows how partnerships can help transform patient care. Working with partners in primary care, the program is advancing integrated care for COPD, severe asthma and lung cancer to support earlier diagnosis, improve patient outcomes, and expand health system capacity.

In Ontario, more than half of new patients in the Best Care program are from rural and lower-income communities, where disease burden is often highest. By helping tackle barriers to earlier detection, diagnosis and treatment, the program is advancing health equity and improving access to care for underserved communities while reducing pressure on emergency departments and hospitals.

In 2025, the program achieved:

22,000 patients connected to guideline-directed care

15,000 avoided primary care visits

2,700 avoided emergency room visits

1,300 avoided hospitalizations

¹ AstraZeneca supports Best Care through grants in partnership with multiple stakeholders, including government and other funding sources.



Lung Health Check in Alberta: Advancing Patient Care and Health Equity

In Alberta, AstraZeneca is supporting a novel approach to earlier screening and diagnosis for people who live far from major centres. Through the **Lung Health Check** program, developed in partnership with **Praxus Health**, **Aceso Medical** and the **Government of Alberta**, mobile lung health services are being brought directly to rural and remote communities, where access to essential COPD and lung cancer early screening and diagnosis is often limited.

The program's pulmonary function testing unit is already operating across Alberta, and a mobile CT unit is expected to launch to **support lung cancer screening**. It shows how partnership can help address barriers and inequities in the health system to ensure that all Canadians, regardless of where they live, can access the care they need. **AstraZeneca contributed \$1 million in funding** for this two-year pilot program.



“ We’re committed to driving positive change beyond our medicines – tackling pressing sustainability challenges including climate change, health equity, and health system resilience. Through partnerships with Best Care, Plan International, the Canadian Cancer Society, and other leading Canadian organizations, we’re working to improve care and access for underserved populations in rural and remote areas, reducing emergency service burdens, strengthening health systems, and taking action on climate and nature.

Gena Restivo

VP, Corporate Affairs & Sustainability, AstraZeneca Canada





Expert Centre for Complement-Mediated Rare Diseases at CHU Sainte-Justine

Alexion, AstraZeneca Rare Disease, is supporting stronger care pathways for patients in Canada living with rare diseases through the **recent launch of the Expert Centre for Complement-Mediated Rare Diseases at CHU Sainte-Justine in Montreal** – the first centre of its kind in Canada.

Created in partnership with the **CHU Sainte-Justine Foundation**, the **Kidney Foundation of Canada (KFOC)**, and the **Quebec Consortium for Drug Discovery (CQDM)**, the Centre is designed to improve the understanding, diagnosis, and treatment of complement-mediated rare diseases across Canada.

Complement-mediated diseases are conditions in which the immune system, specifically the complement proteins, become overactive or dysfunctional and mistakenly attack the body's healthy cells and cause certain diseases. These diseases can cause inflammation or organ damage, requiring treatments to regulate complement activity and protect healthy cells.

Historically, complex laboratory tests for complement-mediated diseases have been sent outside Canada, causing lengthy wait times for patients to receive an accurate diagnosis and treatment. The Centre addresses this by bringing expertise closer to home. By developing local diagnostic capabilities, it will improve patient outcomes, stimulate innovation, strengthen Canada's autonomy in rare disease diagnostics, and position Quebec as a leader in this field – building a more resilient and equitable health system for Canadians.



“Public-private partnerships are essential to accelerate access to new innovative treatments and improve health equity across Canada – especially for people living with rare diseases, who wait an average of five years for an accurate diagnosis.

As a founding partner of the Expert Centre for Complement Mediated Rare Diseases at CHU Sainte-Justine in Montreal, Quebec, Alexion's investment has helped bring critical diagnostic testing back to Canada, reducing wait times and enabling faster, more accurate diagnoses. By bringing these critical capabilities closer to patients and clinicians, we're making care more efficient and helping ensure families receive timely, coordinated support. This collaboration delivers real impact today while building a stronger, more equitable health system for the future.

Karen Heim

VP & General Manager,
Alexion, AstraZeneca Rare
Disease, Canada






There has never been a more exciting time for AstraZeneca Canada in oncology. Our expanding research footprint is fueling a rich pipeline and delivering medicines that are transforming cancer treatment.

However, delivering innovation is only part of the equation. It's important that patients are diagnosed earlier, when treatments can achieve the best possible outcomes. Across Canada, we're partnering with leading hospitals and institutions such as University Health Network and Alberta Precision Laboratories to support earlier and more equitable access to diagnostic testing – so that Canadian patients receive the right treatment at the right time, regardless of where they live.

Tania Molinaro

VP & Head of Oncology,
AstraZeneca Canada





Advancing Canadian Cancer Research Through Partnerships

AstraZeneca is supporting Canadian-led research that can improve outcomes for people living with cancer.

Through its partnership with **Lung Cancer Canada** and the **Lung Ambition Alliance**, AstraZeneca supports the **Lung Ambition Awards**, a Canadian research program focused on improving outcomes for people living with lung cancer. Now in its fourth year, the program has funded six Canadian researchers to date, supporting leading-edge research projects focused on earlier detection, diagnostic optimization, treatment pathway integration and health equity. In 2025, **the awards granted \$100,000 to two Canadian research teams** developing new approaches to improve early lung cancer diagnosis and the patient experience.

AstraZeneca is collaborating with the **Leukemia & Lymphoma Society of Canada** to co-fund the **Operating Grants in Blood Cancer**, a program designed to support Canadian research that can improve the understanding, diagnosis and treatment of blood cancers. The grants are valued at up to **\$100,000 annually for two years**, with emphasis on community partnership integration, patient impact and the potential to create new knowledge.

Together, these programs demonstrate how partnerships can help advance patient-focused research with the potential to improve care.



RAREvolution Scholarship: Opening Doors for Youth Living with Rare Diseases

Alexion, AstraZeneca Rare Disease, partnered with the Canadian Rare Disease Network (CRDN) to launch the **RAREvolution Scholarship**, Canada's first pan-rare disease scholarship initiative for young people in the rare disease community who are pursuing post-secondary education.

Students living with rare diseases often face financial, health-related, and accessibility barriers that can make education harder to access. The RAREvolution Scholarship is designed to reduce those barriers, awarding a minimum of 15 scholarships to undergraduate and graduate students across Canada. Beyond financial support, the program fosters peer connection, shared learning, and leadership among students navigating post-secondary education within the rare disease context.

More than a scholarship, this is an investment in future potential. It recognizes lived experience, resilience, and promise – qualities that shape leaders, innovators, and advocates. By supporting access to education, the program helps ensure that opportunity, independence, and purpose remain within reach for young Canadians affected by rare disease.



“The RAREvolution Scholarship represents an important milestone for the rare disease community in Canada. Made possible through support from Alexion, AstraZeneca Rare Disease, it is the first pan-rare initiative of its kind – helping reduce barriers to post-secondary education while empowering young people with lived experience to become leaders, advocates, and changemakers. Initiatives like this help shift the narrative around rare diseases – ensuring these voices are seen, heard, and meaningfully included – and signal a strong commitment to building a more equitable and responsive health system.”

Svenja Espenhahn

Canadian Rare Disease
Network (CRDN)






Eureka Fellowship for Youth Changemakers

AstraZeneca is supporting the next generation of sustainability leaders in Canada through the **Eureka Fellowship for Youth Changemakers**, developed in partnership with **Plan International Canada**. Introduced in 2024, the fellowship is designed to identify and support young Canadians addressing critical sustainability challenges and to amplify the impact of their work.

In 2025, AstraZeneca and Plan International Canada launched the program's second cohort, with **10 Fellows** selected for **2025-26**. Their work spans health equity, climate action, and biodiversity, and shows the power of youth to drive meaningful sustainability impact. Examples of initiatives being advanced through the fellowship include:



Expanding access to essential cancer support services – including financial, nutritional, and emotional care – in marginalized communities.



Supporting ocean conservation by using AI and sound recordings from underwater microphones (hydrophones) to monitor endangered marine mammals and reduce underwater noise pollution.




Improving health literacy in diverse and newcomer communities across Canada by using AI to deliver culturally tailored, accessible health information.




Sustainability

AstraZeneca in Canada recognizes the connection between healthy people, healthy communities, and a healthy planet. Through its global Ambition Zero Carbon strategy and Canadian initiatives, the company is reducing emissions and building sustainability into the way it operates and grows, while also supporting health equity, community resilience, and the next-generation of sustainability leaders.

Key 2025 Sustainability Highlights:



Achieved Gold status in the Government of **Canada's Net-Zero Challenge**, committing to achieve net-zero emissions by 2050.




Transitioned 98% of our corporate vehicle fleet in Canada to fully electric vehicles.



Continued expansion of Electric Product Information (ePI), which helps reduce paper usage and improve patient access to medicine information.



450 AstraZeneca and Alexion colleagues participated in the inaugural **OceanWise shoreline cleanups** in the Greater Toronto Area.



Green by Design: Our Next-Generation Head Office and Innovation Hub

AstraZeneca's **new 240,000 sq. ft. head office and innovation hub** in Mississauga is designed with sustainability at its core. **Designed to achieve LEED certification²**, the site supports the company's rapidly growing and diverse footprint in Canada while reducing the environmental impact of its operations. During construction, 97% of waste was recycled or repurposed. The site also includes:




Waste minimization and efficiency practices



Smart lighting systems and high-efficiency water fixtures



Access to public transit and green space



Extensive EV charging infrastructure.

² LEED - Canada Green Building Council (CAGBC)



People & Community

In Canada, AstraZeneca is helping develop future leaders while supporting communities across the country through volunteering, charitable giving, and community partnerships.

Early Careers

AstraZeneca is investing in Canada's next generation of life-sciences talent through partnerships with universities and colleges in Southern Ontario and early-career programs spanning science, business, regulatory affairs, and pharmacy. Approximately 200 students have joined the company through these programs.

The impact is tangible at every level of the organization. **AstraZeneca Canada President Gaby Bourbara joined the company as an MBA co-op student and has since built a career spanning 25 years, illustrating the long-term career pathways these programs create.**

AstraZeneca's long-standing partnership with the **University of Toronto's Master of Biotechnology (MBiotech) program** has been in place since 2007 and continues to grow, with 2026 set to be its largest cohort to date.



More than 150 students hired through this partnership.



80% receiving a contract extension or converted to full-time employment.





AstraZeneca’s partnership with **McMaster University’s Master of Biomedical Discovery and Commercialization program**, in place since 2018, continues to grow, with 2026 representing the program’s largest intake to-date. More than 40 students have been hired through the partnership, with a 100% conversion rate into full-time roles since 2021.

New and Growing Partnerships

AstraZeneca is expanding its early-careers footprint across Ontario, with new partnerships that deepen its reach into pharmacy, regulatory affairs and commercialization:



Leslie Dan Faculty of Pharmacy,
Pharmacy Industry Residency
Program



Pharmaceutical & Healthcare
Management & Innovation



Regulatory Affairs and Quality
Assurance Program



Masters in Biotechnology
Management



Doctor of Pharmacy program



Community Engagement

The ACT Foundation of Canada

As a founding partner of **The ACT Foundation of Canada**, AstraZeneca Canada has donated more than \$2 million to help support and expand the organization’s CPR (cardiopulmonary resuscitation) and defibrillator training for young people across Canada. The ACT Foundation’s program has been established in more than 1,800 high schools across Canada, empowering students with practical, life-saving skills such as CPR, first aid, and emergency response to take charge and help during emergencies in their schools, families, and communities



More than 6.6 million youth have received CPR training.



Roughly 350,000 students are trained annually.



10,700 teachers have been trained as CPR instructors for their students.



More than 60,000 durable mannequins have been donated to schools.



Appendix Methodology

AstraZeneca's economic impact in Canada was estimated by combining AstraZeneca internal data with official economic data published by Statistics Canada.

AstraZeneca Canada supplied data on direct employment and operations, as well as supplier-level procurement data, including spend and supplier location.

Statistics Canada input-output multipliers were used to estimate how AstraZeneca's spending supports economic activity and jobs across Canada, capturing direct effects, supply chain (indirect) effects and employee spending (induced) effects.

The total Gross Value Added (GVA) and jobs supported are calculated as the sum of three components:

- Direct impact: Activity generated by AstraZeneca's own operations in Canada, measured through its employees and in-country operations.
- Supply chain impact: Activity supported by the businesses AstraZeneca purchases from, as well as by the suppliers of those suppliers across the full supply chain.
- Employee spending impact: Additional activity supported

when people whose jobs are linked to AstraZeneca (directly or indirectly) spend their wages in the wider economy, for example, on housing, transport, and leisure.

Where results are shown by province, they represent the geographic distribution of AstraZeneca employees and suppliers in the modelling dataset.

The analysis excludes the wider health and productivity benefits of AstraZeneca's medicines. These impacts would be in addition to the GVA and jobs reported, so the figures should be interpreted as conservative estimates.



 **PUBLIC FIRST**
A SHGH Company
Deep insights. Straight advice. Real results.

2026

